Browse by category

Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity

Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with...

Lilly's Zepbound (tirzepatide) achieved total mean weight loss of 26.0% from baseline to 88 weeks

Detailed results from SURMOUNT-4 have shown Zepbound (tirzepatide) injection achieved superior mean percent change in body weight...

Zepbound (tirzepatide) available in US pharmacies for adults living with obesity

Eli Lilly and Company has announced that Zepbound (tirzepatide) injection is now available in US pharmacies for adults with obesity (with...

FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management

The FDA has approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that...

Gastric pouch resizing for recurrent weight gain promotes weight stabilisation in well-selected patients

4 days ago

COVID-19 pandemic: Bariatric surgery patients showed an increase in the percentage of weight regain

4 days ago

Semaglutide and liraglutide may reduce alcohol consumption in individuals with AUD

4 days ago

Weekly Digest